Fresh2 Group Ltd ADR FRES
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FRES is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.42
- Day Range
- $0.39–0.44
- 52-Week Range
- $0.30–6.00
- Bid/Ask
- $0.40 / $0.44
- Market Cap
- $10.23 Mil
- Volume/Avg
- 72,934 / 171,997
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 75
- Website
- https://www.fresh2.co
Valuation
|
Metric
|
FRES
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.29 |
Price/Sales | 1.08 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FRES
|
|---|---|
Quick Ratio | 0.22 |
Current Ratio | 0.46 |
Interest Coverage | −214.41 |
Quick Ratio
FRES
Profitability
|
Metric
|
FRES
|
|---|---|
Return on Assets (Normalized) | −107.17% |
Return on Equity (Normalized) | −335.57% |
Return on Invested Capital (Normalized) | −205.15% |
Return on Assets
FRES
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ljbttxbws | Drqq | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vjjcqsqws | Xlxbjnw | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rskbqcmn | Lrknptq | $107.6 Bil | |
MRNA
| Moderna Inc | Ttfljsc | Kwcxv | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Nrqdxntc | Hvwp | $22.3 Bil | |
ARGX
| argenx SE ADR | Lqztjczw | Rhgpn | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fgskgmw | Htbhz | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nxyqpkws | Kdyyhyr | $15.3 Bil | |
INCY
| Incyte Corp | Gqhymnkx | Djgkjnf | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tyyjkxtdm | Nvgfxw | $12.7 Bil |